Request Complimentary Product Samples
FOSAMAX PLUS D^™ (alendronate sodium/cholecalciferol)

FOSAMAX^® (alendronate sodium) 

•  Prescribing Information
• Patient Product Information (Once Daily)
• Patient Product Information (Once Weekly)

FOSAMAX PLUS D^™(alendronate sodium/cholecalciferol) 

•  Prescribing Information
•  Patient Product Information

Registered and validated MDs/DOs may print out a form to request complimentary samples of Merck products.

To request complimentary samples, you must sign in. You will then be shown a list of the different complimentary sample formulations for that product that you may request. When you finalize your requests, you will need to print out a Sample Request Form. This form must then be signed, dated, and returned to Merck via fax or mail using the fax number or address specified on the form. You should receive the samples requested via UPS delivery within 14 business days of Merck receiving the completed form.

Viewing files designated with requires a PDF reader

IMPORTANT PRODUCT INFORMATION: FOSAMAX and FOSAMAX PLUS D are indicated for the treatment of osteoporosis in postmenopausal women. For the treatment of osteoporosis, FOSAMAX and FOSAMAX PLUS D increase bone mass and reduce the incidence of fractures, including those of the hip and spine (vertebral compression fractures). FOSAMAX and FOSAMAX PLUS D are contraindicated in patients with esophageal abnormalities which delay esophageal emptying (eg, stricture or achalasia) and in patients unable to stand or sit upright for at least 30 minutes. Patients at increased risk of aspiration should not receive FOSAMAX oral solution. FOSAMAX and FOSAMAX PLUS D are contraindicated in patients with hypocalcemia (see WARNINGS AND PRECAUTIONS) and in patients with hypersensitivity to any component of these products. Hypersensitivity reactions including urticaria and angioedema have been reported. FOSAMAX and FOSAMAX PLUS D, like other bisphosphonates, may cause local irritation of the upper gastrointestinal mucosa. In postmarketing experience, severe and occasionally incapacitating bone, joint, and/or muscle pain has been reported in patients taking bisphosphonates that are approved for the prevention and treatment of osteoporosis. The time to onset of symptoms varied from one day to several months after starting the drug. Discontinue use if severe symptoms develop. Most patients had relief of symptoms after stopping treatment. Before prescribing FOSAMAX or FOSAMAX PLUS D, please see the Prescribing Information and Patient Product Information.